SDX 308

Known as: SDX-308, SDX308 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2008
0120062008

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2008
Review
2008
Non-steroidal anti-inflammatory drugs (NSAIDs) comprise the group of structurally diverse but similarly acting compounds that are… (More)
Is this relevant?
2007
2007
Multiple myeloma is characterized by increased osteoclast activity that results in bone destruction and lytic lesions. With the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2007
2007
Multiple myeloma is characterized by increased osteoclast activity that results in bone destruction and lytic lesions. With the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2007
Review
2007
Multiple myeloma (MM) is a hematologic malignancy characterized by dysregulated proliferation of plasma cells and increased… (More)
Is this relevant?
2007
2007
We have reported previously that R-enantiomer of etodolac (R-etodolac), which is under investigation in phase 2 clinical trials… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
Review
2007
Review
2007
Non-steroidal anti-inflammatory drugs have been shown to inhibit carcinogenesis in colon cancer, and to induce apoptosis in a… (More)
Is this relevant?
2007
2007
SDX-308 and SDX-309 are potent indole-pyran analogues of SDX-101 (R-etodolac) which has anti-tumour activity unrelated to… (More)
  • figure 2
  • table 1
  • table 2
  • figure 3
  • figure 4
Is this relevant?
2006
2006
SDX-101 is the non-cyclooxygenase 2-inhibiting R-enantiomer of the non-steroid anti-inflammatory drug etodolac, and has anti… (More)
  • table 1
  • table 2
  • table 3
  • figure 2
  • table 4
Is this relevant?